Tarlatamab-dlle. bulk supplier for pharma manufacturers

Tarlatamab-Dlle. 1 mg, 10 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1 mg, 10 mg

Reference Brands: Imdelltra (USA), Imdylltra (EU/UK)

Tarlatamab-dlle is a bispecific T-cell engager (BiTE) antibody that binds DLL3 on small cell lung cancer cells and CD3 on T cells, enabling targeted immune killing of tumor cells. It is approved for adults with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. It has shown meaningful response rates and durable clinical benefit in resistant disease. The treatment is given by step-up intravenous infusion to reduce the risk of cytokine release syndrome. Patients are monitored closely for immune-related reactions and neurological side effects.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Tarlatamab-Dlle.? List it or send an offer →

Product Description:

Tarlatamab links DLL3 on a small cell lung cancer cell to CD3 on a T cell. DLL3 is an unusual target: it is expressed on the surface of the great majority of small cell lung cancers and essentially not at all on normal adult tissue, which is precisely the profile needed for a T-cell engager, where any off-tumour expression becomes on-target toxicity. It is the first meaningful advance in relapsed small cell lung cancer in decades.

It is used for extensive-stage small cell lung cancer that has progressed after platinum-based chemotherapy, a setting where responses were previously brief and uncommon. It is given by intravenous infusion with step-up dosing. Cytokine release syndrome occurs in most patients, is concentrated in the first two doses, and requires inpatient monitoring at initiation. Immune effector cell-associated neurotoxicity, which in small cell lung cancer must be distinguished from paraneoplastic neurological syndromes, also occurs, along with cytopenias and infection.

Sourcing notes. Originator biologic under patent, marketed under different brand names in different regions. Two vial strengths correspond to the step-up and full doses and both are required to start a patient. Cold chain at 2–8 degrees. The receiving centre needs inpatient capacity for the first cycle.

How Tarlatamab-Dlle. is supplied today, and licensing ahead of patent expiry

Tarlatamab-Dlle. is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Tarlatamab-Dlle., hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Tarlatamab-Dlle. supply →

Back to Listing

Frequently Asked Questions

Tarlatamab-dlle is used for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in adults who have disease progression after platinum-based chemotherapy.

It is made from a bispecific T-cell engager (BiTE) antibody construct that binds to DLL3 on tumor cells and CD3 on T-cells to trigger targeted immune-mediated killing.

The trade name is Imdelltra.

It is manufactured and marketed by Amgen Inc.

The generic name is tarlatamab-dlle.

The brand name is Imdelltra.

It is manufactured by Amgen at its biologics production facilities in the United States.

Tarlatamab is sold as Imdelltra and Imdylltra. It is developed and sold by Amgen. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.